Skip to main content
Top
Published in: Fibrogenesis & Tissue Repair 1/2012

Open Access 01-12-2012 | Proceedings

Progression of renal fibrosis: the underestimated role of endothelial alterations

Authors: Dominique Guerrot, Jean-Claude Dussaule, Panagiotis Kavvadas, Jean-Jacques Boffa, Christos E Chadjichristos, Christos Chatziantoniou

Published in: Fibrogenesis & Tissue Repair | Special Issue 1/2012

Login to get access

Abstract

The vasculature of the kidney is a heterogeneous structure, whose functional integrity is essential for the regulation of renal function. Owing to the importance of the endothelium in vascular biology, chronic endothelial alterations are therefore susceptible to impair multiple aspects of renal physiology and, in turn, to contribute to renal fibrosis. Although systemic endothelial dysfunction is undoubtedly associated with chronic kidney disease, the role of the renal endothelium in the initiation and the progression of renal fibrosis remains largely elusive. In this article, we critically review recent evidence supporting direct and indirect contributions of renal endothelial alterations to fibrosis in the kidney. Specifically, the potential implications of renal endothelial dysfunction and endothelial paucity in parenchymal hypoxia, in the regulation of local inflammation, and in the generation of renal mesenchymal cells are reviewed. We thereafter discuss therapeutic perspectives targeting renal endothelial alterations during the initiation and the progression of renal fibrogenesis.
Literature
1.
go back to reference Félétou M, Vanhoutte PM: Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006, 291: H985-1002. 10.1152/ajpheart.00292.2006.CrossRefPubMed Félétou M, Vanhoutte PM: Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006, 291: H985-1002. 10.1152/ajpheart.00292.2006.CrossRefPubMed
2.
go back to reference Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007, 115: 1285-1295.PubMed Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007, 115: 1285-1295.PubMed
3.
go back to reference Joannides R, Haefeli WE, Linder L, et al: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995, 91: 1314-1319. 10.1161/01.CIR.91.5.1314.CrossRefPubMed Joannides R, Haefeli WE, Linder L, et al: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995, 91: 1314-1319. 10.1161/01.CIR.91.5.1314.CrossRefPubMed
4.
go back to reference Thuillez C, Richard V: Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens. 2005, S21-25. 19 Suppl 1 Thuillez C, Richard V: Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens. 2005, S21-25. 19 Suppl 1
5.
go back to reference Constans J, Conri C: Circulating markers of endothelial function in cardiovascular disease: Clin Chim Acta. Netherlands. 2006, 33-47. Constans J, Conri C: Circulating markers of endothelial function in cardiovascular disease: Clin Chim Acta. Netherlands. 2006, 33-47.
6.
go back to reference Rabelink TJ, de Boer HC, van Zonneveld AJ: Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol. 2010, 6: 404-414. 10.1038/nrneph.2010.65.CrossRefPubMed Rabelink TJ, de Boer HC, van Zonneveld AJ: Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol. 2010, 6: 404-414. 10.1038/nrneph.2010.65.CrossRefPubMed
7.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351: 1296-1305. 10.1056/NEJMoa041031.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351: 1296-1305. 10.1056/NEJMoa041031.CrossRefPubMed
8.
go back to reference Zoccali C: Endothelial dysfunction in CKD: a new player in town?. Nephrol Dial Transplant. 2008 Zoccali C: Endothelial dysfunction in CKD: a new player in town?. Nephrol Dial Transplant. 2008
9.
go back to reference Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol. 2004, 15: 538-548. 10.1097/01.ASN.0000111744.00916.E6.CrossRefPubMed Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol. 2004, 15: 538-548. 10.1097/01.ASN.0000111744.00916.E6.CrossRefPubMed
10.
go back to reference Cooke JP: Asymmetrical dimethylarginine: the Uber marker?. Circulation. 2004, 109: 1813-1818. 10.1161/01.CIR.0000126823.07732.D5.CrossRefPubMed Cooke JP: Asymmetrical dimethylarginine: the Uber marker?. Circulation. 2004, 109: 1813-1818. 10.1161/01.CIR.0000126823.07732.D5.CrossRefPubMed
11.
go back to reference Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD: Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 2003, 18: 892-898. 10.1093/ndt/gfg080.CrossRefPubMed Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD: Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 2003, 18: 892-898. 10.1093/ndt/gfg080.CrossRefPubMed
12.
go back to reference Mihout F, Shweke N, Bige N, et al: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol. 2011, 223: 37-45. 10.1002/path.2769.CrossRefPubMed Mihout F, Shweke N, Bige N, et al: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol. 2011, 223: 37-45. 10.1002/path.2769.CrossRefPubMed
13.
go back to reference Fliser D, Kronenberg F, Kielstein JT, et al: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005, 16: 2456-2461. 10.1681/ASN.2005020179.CrossRefPubMed Fliser D, Kronenberg F, Kielstein JT, et al: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005, 16: 2456-2461. 10.1681/ASN.2005020179.CrossRefPubMed
14.
go back to reference Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007, 87: 245-313. 10.1152/physrev.00044.2005.CrossRefPubMed Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007, 87: 245-313. 10.1152/physrev.00044.2005.CrossRefPubMed
15.
go back to reference Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC: Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation. 1999, 99: 2185-2191. 10.1161/01.CIR.99.16.2185.CrossRefPubMed Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC: Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation. 1999, 99: 2185-2191. 10.1161/01.CIR.99.16.2185.CrossRefPubMed
16.
go back to reference Mimura I, Nangaku M: The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010, 6: 667-678. 10.1038/nrneph.2010.124.CrossRefPubMed Mimura I, Nangaku M: The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010, 6: 667-678. 10.1038/nrneph.2010.124.CrossRefPubMed
17.
go back to reference Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int. 2000, 58: 2351-2366. 10.1046/j.1523-1755.2000.00419.x.CrossRefPubMed Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int. 2000, 58: 2351-2366. 10.1046/j.1523-1755.2000.00419.x.CrossRefPubMed
18.
go back to reference Leonard MO, Cottell DC, Godson C, Brady HR, Taylor CT: The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J Biol Chem. 2003, 278: 40296-40304. 10.1074/jbc.M302560200.CrossRefPubMed Leonard MO, Cottell DC, Godson C, Brady HR, Taylor CT: The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J Biol Chem. 2003, 278: 40296-40304. 10.1074/jbc.M302560200.CrossRefPubMed
19.
go back to reference Brodsky SV, Yamamoto T, Tada T, et al: Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol. 2002, 282: F1140-1149.CrossRefPubMed Brodsky SV, Yamamoto T, Tada T, et al: Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol. 2002, 282: F1140-1149.CrossRefPubMed
20.
go back to reference Choi YJ, Chakraborty S, Nguyen V, et al: Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol. 2000, 31: 1491-1497. 10.1053/hupa.2000.20373.CrossRefPubMed Choi YJ, Chakraborty S, Nguyen V, et al: Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol. 2000, 31: 1491-1497. 10.1053/hupa.2000.20373.CrossRefPubMed
21.
go back to reference Kwon O, Hong SM, Sutton TA, Temm CJ: Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol. 2008, 295: F351-359. 10.1152/ajprenal.90276.2008.PubMedCentralCrossRefPubMed Kwon O, Hong SM, Sutton TA, Temm CJ: Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol. 2008, 295: F351-359. 10.1152/ajprenal.90276.2008.PubMedCentralCrossRefPubMed
22.
go back to reference Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR: Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant. 2010, 25: 1079-1087. 10.1093/ndt/gfp605.PubMedCentralCrossRefPubMed Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR: Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant. 2010, 25: 1079-1087. 10.1093/ndt/gfp605.PubMedCentralCrossRefPubMed
23.
go back to reference Ochodnický P, Henning RH, Buikema HJ, de Zeeuw D, Provoost AP, van Dokkum RP: Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. Am J Physiol Renal Physiol. 2010, 298: F625-633. 10.1152/ajprenal.00289.2009.CrossRefPubMed Ochodnický P, Henning RH, Buikema HJ, de Zeeuw D, Provoost AP, van Dokkum RP: Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. Am J Physiol Renal Physiol. 2010, 298: F625-633. 10.1152/ajprenal.00289.2009.CrossRefPubMed
24.
go back to reference Bojakowski K, Abramczyk P, Bojakowska M, Zwolinska A, Przybylski J, Gaciong Z: Fucoidan improves the renal blood flow in the early stage of renal ischemia/reperfusion injury in the rat. J Physiol Pharmacol. 2001, 52: 137-143.PubMed Bojakowski K, Abramczyk P, Bojakowska M, Zwolinska A, Przybylski J, Gaciong Z: Fucoidan improves the renal blood flow in the early stage of renal ischemia/reperfusion injury in the rat. J Physiol Pharmacol. 2001, 52: 137-143.PubMed
25.
go back to reference Kato N, Yuzawa Y, Kosugi T, et al: The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. J Am Soc Nephrol. 2009, 20: 1565-1576. 10.1681/ASN.2008090957.PubMedCentralCrossRefPubMed Kato N, Yuzawa Y, Kosugi T, et al: The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. J Am Soc Nephrol. 2009, 20: 1565-1576. 10.1681/ASN.2008090957.PubMedCentralCrossRefPubMed
26.
go back to reference De Vriese AS, Endlich K, Elger M, et al: The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol. 1999, 10: 2510-2517.PubMed De Vriese AS, Endlich K, Elger M, et al: The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol. 1999, 10: 2510-2517.PubMed
27.
go back to reference Asgeirsdóttir SA, Zwiers PJ, Morselt HW, et al: Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol. 2008, 294: F554-561. 10.1152/ajprenal.00391.2007.CrossRefPubMed Asgeirsdóttir SA, Zwiers PJ, Morselt HW, et al: Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol. 2008, 294: F554-561. 10.1152/ajprenal.00391.2007.CrossRefPubMed
28.
go back to reference Kelly KJ, Williams WW, Colvin RB, Bonventre JV: Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA. 1994, 91: 812-816. 10.1073/pnas.91.2.812.PubMedCentralCrossRefPubMed Kelly KJ, Williams WW, Colvin RB, Bonventre JV: Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA. 1994, 91: 812-816. 10.1073/pnas.91.2.812.PubMedCentralCrossRefPubMed
29.
go back to reference Kelly KJ, Williams WW, Colvin RB, et al: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest. 1996, 97: 1056-1063. 10.1172/JCI118498.PubMedCentralCrossRefPubMed Kelly KJ, Williams WW, Colvin RB, et al: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest. 1996, 97: 1056-1063. 10.1172/JCI118498.PubMedCentralCrossRefPubMed
30.
go back to reference Sohl G, Willecke K: Gap junctions and the connexin protein family. Cardiovasc Res. 2004, 62: 228-232. 10.1016/j.cardiores.2003.11.013.CrossRefPubMed Sohl G, Willecke K: Gap junctions and the connexin protein family. Cardiovasc Res. 2004, 62: 228-232. 10.1016/j.cardiores.2003.11.013.CrossRefPubMed
31.
32.
go back to reference Scheckenbach KE, Crespin S, Kwak BR, Chanson M: Connexin Channel-Dependent Signaling Pathways in Inflammation. J Vasc Res Basel. 2010, 91-103. Scheckenbach KE, Crespin S, Kwak BR, Chanson M: Connexin Channel-Dependent Signaling Pathways in Inflammation. J Vasc Res Basel. 2010, 91-103.
33.
go back to reference Chadjichristos CE, Scheckenbach KE, van Veen TA, et al: Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation. 2010, 121: 123-131. 10.1161/CIRCULATIONAHA.109.867176.CrossRefPubMed Chadjichristos CE, Scheckenbach KE, van Veen TA, et al: Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation. 2010, 121: 123-131. 10.1161/CIRCULATIONAHA.109.867176.CrossRefPubMed
34.
go back to reference Veliz LP, Gonzalez FG, Duling BR, Saez JC, Boric MP: Functional role of gap junctions in cytokine-induced leukocyte adhesion to endothelium in vivo. Am J Physiol Heart Circ Physiol. 2008, 295: H1056-H1066. 10.1152/ajpheart.00266.2008.PubMedCentralCrossRefPubMed Veliz LP, Gonzalez FG, Duling BR, Saez JC, Boric MP: Functional role of gap junctions in cytokine-induced leukocyte adhesion to endothelium in vivo. Am J Physiol Heart Circ Physiol. 2008, 295: H1056-H1066. 10.1152/ajpheart.00266.2008.PubMedCentralCrossRefPubMed
35.
go back to reference Parthasarathi K, Ichimura H, Monma E, et al: Connexin 43 mediates spread of Ca2+-dependent proinflammatory responses in lung capillaries. J Clin Invest. 2006, 116: 2193-2200. 10.1172/JCI26605.PubMedCentralCrossRefPubMed Parthasarathi K, Ichimura H, Monma E, et al: Connexin 43 mediates spread of Ca2+-dependent proinflammatory responses in lung capillaries. J Clin Invest. 2006, 116: 2193-2200. 10.1172/JCI26605.PubMedCentralCrossRefPubMed
36.
go back to reference Chadjichristos CE, Morel S, Derouette JP, et al: Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells: Circ Res. United States. 2008, 653-660. Chadjichristos CE, Morel S, Derouette JP, et al: Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells: Circ Res. United States. 2008, 653-660.
37.
go back to reference Dussaule JC, Guerrot D, Huby AC, et al: The role of cell plasticity in progression and reversal of renal fibrosis. Int J Exp Pathol. 2011 Dussaule JC, Guerrot D, Huby AC, et al: The role of cell plasticity in progression and reversal of renal fibrosis. Int J Exp Pathol. 2011
38.
go back to reference Galichon P, Hertig A: Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?. Fibrogenesis Tissue Repair. 2011, 4: 11-10.1186/1755-1536-4-11.PubMedCentralCrossRefPubMed Galichon P, Hertig A: Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?. Fibrogenesis Tissue Repair. 2011, 4: 11-10.1186/1755-1536-4-11.PubMedCentralCrossRefPubMed
39.
go back to reference Kriz W, Kaissling B, Le Hir M: Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?. J Clin Invest. 2011, 121: 468-474. 10.1172/JCI44595.PubMedCentralCrossRefPubMed Kriz W, Kaissling B, Le Hir M: Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?. J Clin Invest. 2011, 121: 468-474. 10.1172/JCI44595.PubMedCentralCrossRefPubMed
40.
go back to reference Piera-Velazquez S, Li Z, Jimenez SA: Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders. Am J Pathol. 2011, 179: 1074-1080. 10.1016/j.ajpath.2011.06.001.PubMedCentralCrossRefPubMed Piera-Velazquez S, Li Z, Jimenez SA: Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders. Am J Pathol. 2011, 179: 1074-1080. 10.1016/j.ajpath.2011.06.001.PubMedCentralCrossRefPubMed
41.
go back to reference Zeisberg EM, Tarnavski O, Zeisberg M, et al: Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007, 13: 952-961. 10.1038/nm1613.CrossRefPubMed Zeisberg EM, Tarnavski O, Zeisberg M, et al: Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007, 13: 952-961. 10.1038/nm1613.CrossRefPubMed
42.
go back to reference Kizu A, Medici D, Kalluri R: Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol. 2009, 175: 1371-1373. 10.2353/ajpath.2009.090698.PubMedCentralCrossRefPubMed Kizu A, Medici D, Kalluri R: Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol. 2009, 175: 1371-1373. 10.2353/ajpath.2009.090698.PubMedCentralCrossRefPubMed
43.
go back to reference Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R: Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008, 19: 2282-2287. 10.1681/ASN.2008050513.PubMedCentralCrossRefPubMed Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R: Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008, 19: 2282-2287. 10.1681/ASN.2008050513.PubMedCentralCrossRefPubMed
44.
go back to reference Li J, Qu X, Yao J, et al: Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes. 2010, 59: 2612-2624. 10.2337/db09-1631.PubMedCentralCrossRefPubMed Li J, Qu X, Yao J, et al: Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes. 2010, 59: 2612-2624. 10.2337/db09-1631.PubMedCentralCrossRefPubMed
45.
go back to reference Basile DP, Friedrich JL, Spahic J, et al: Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol. 2011, 300: F721-733. 10.1152/ajprenal.00546.2010.PubMedCentralCrossRefPubMed Basile DP, Friedrich JL, Spahic J, et al: Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol. 2011, 300: F721-733. 10.1152/ajprenal.00546.2010.PubMedCentralCrossRefPubMed
46.
go back to reference Melo-Filho NM, Belmiro CL, Gonçalves RG, et al: Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event?. Am J Physiol Renal Physiol. 2010, 299: F1299-1307. 10.1152/ajprenal.00217.2010.CrossRefPubMed Melo-Filho NM, Belmiro CL, Gonçalves RG, et al: Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event?. Am J Physiol Renal Physiol. 2010, 299: F1299-1307. 10.1152/ajprenal.00217.2010.CrossRefPubMed
47.
go back to reference Choi DE, Jeong JY, Lim BJ, et al: Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol. 2009, 297: F362-370. 10.1152/ajprenal.90609.2008.CrossRefPubMed Choi DE, Jeong JY, Lim BJ, et al: Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol. 2009, 297: F362-370. 10.1152/ajprenal.90609.2008.CrossRefPubMed
48.
go back to reference Asgeirsdóttir SA, Kamps JA, Bakker HI, et al: Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol. 2007, 72: 121-131. 10.1124/mol.107.034140.CrossRefPubMed Asgeirsdóttir SA, Kamps JA, Bakker HI, et al: Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol. 2007, 72: 121-131. 10.1124/mol.107.034140.CrossRefPubMed
49.
go back to reference Masuda Y, Shimizu A, Mori T, et al: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol. 2001, 159: 599-608. 10.1016/S0002-9440(10)61731-2.PubMedCentralCrossRefPubMed Masuda Y, Shimizu A, Mori T, et al: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol. 2001, 159: 599-608. 10.1016/S0002-9440(10)61731-2.PubMedCentralCrossRefPubMed
50.
go back to reference Chade AR, Zhu XY, Krier JD, et al: Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells. 2010, 28: 1039-1047. 10.1002/stem.426.PubMedCentralCrossRefPubMed Chade AR, Zhu XY, Krier JD, et al: Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells. 2010, 28: 1039-1047. 10.1002/stem.426.PubMedCentralCrossRefPubMed
51.
go back to reference Stokman G, Stroo I, Claessen N, Teske GJ, Florquin S, Leemans JC: SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol Dial Transplant. 2010, 25: 3852-3859. 10.1093/ndt/gfq311.CrossRefPubMed Stokman G, Stroo I, Claessen N, Teske GJ, Florquin S, Leemans JC: SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol Dial Transplant. 2010, 25: 3852-3859. 10.1093/ndt/gfq311.CrossRefPubMed
Metadata
Title
Progression of renal fibrosis: the underestimated role of endothelial alterations
Authors
Dominique Guerrot
Jean-Claude Dussaule
Panagiotis Kavvadas
Jean-Jacques Boffa
Christos E Chadjichristos
Christos Chatziantoniou
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Fibrogenesis & Tissue Repair / Issue Special Issue 1/2012
Electronic ISSN: 1755-1536
DOI
https://doi.org/10.1186/1755-1536-5-S1-S15

Other articles of this Special Issue 1/2012

Fibrogenesis & Tissue Repair 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.